Cargando…
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy
INTRODUCTION: Basal-like breast cancers (BLBCs) are very aggressive, and present serious clinical challenges as there are currently no targeted therapies available. We determined the regulatory role of Y-box binding protein-1 (YB-1) on epidermal growth factor receptor (EGFR) overexpression in BLBC,...
Autores principales: | Stratford, Anna L, Habibi, Golareh, Astanehe, Arezoo, Jiang, Helen, Hu, Kaiji, Park, Eugene, Shadeo, Ashleen, Buys, Timon PH, Lam, Wan, Pugh, Trevor, Marra, Marco, Nielsen, Torsten O, Klinge, Uwe, Mertens, Peter R, Aparicio, Samuel, Dunn, Sandra E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242657/ https://www.ncbi.nlm.nih.gov/pubmed/17875215 http://dx.doi.org/10.1186/bcr1767 |
Ejemplares similares
-
YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression
por: Wu, Joyce, et al.
Publicado: (2007) -
Comprehensive copy number profiles of breast cancer cell model genomes
por: Shadeo, Ashleen, et al.
Publicado: (2006) -
Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004) -
ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
por: Williams, K J, et al.
Publicado: (2002) -
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)